ProCE Banner Activity

New Data on BTK Inhibitors for CLL and MCL: Experts Discuss EHA 2022

Clinical Thought

In this commentary, 2 experts discuss the implications of clinical trial data presented at EHA 2022 on BTK inhibitor–based treatments for patients with chronic lymphocytic leukemia and mantle cell lymphoma.

Released: July 20, 2022

Expiration: July 19, 2023

Share

Faculty

Othman Al-Sawaf

Othman Al-Sawaf, MD

Hematologist & Medical Oncologist
Principal Investigator
University Hospital of Cologne
German CLL Study Group
Cologne, Germany

Lydia Scarfò

Lydia Scarfò, MD

Assistant Professor
Internal Medicine
Università Vita-Salute San Raffaele
Consultant Hematologist
Strategic Research Program on CLL
Milan, Italy

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by an educational grant from

Lilly

Faculty Disclosure

Primary Author

Othman Al-Sawaf, MD

Hematologist & Medical Oncologist
Principal Investigator
University Hospital of Cologne
German CLL Study Group
Cologne, Germany

Othman Al-Sawaf, MD: honoraria: AbbVie, Adaptive Biotechnologies, Ascentage, AstraZeneca, BeiGene, Gilead Sciences, Janssen-Cilag, Roche; consultant/advisor: AbbVie, Gilead Sciences, Janssen-Cilag, Roche; researcher (institution): AbbVie, BeiGene, Janssen/Pharmacyclics, Roche; travel/accommodations/expenses: AbbVie, Gilead Sciences, Janssen-Cilag, Roche.

Lydia Scarfò, MD

Assistant Professor
Internal Medicine
Università Vita-Salute San Raffaele
Consultant Hematologist
Strategic Research Program on CLL
Milan, Italy

Lydia Scarfò, MD: honoraria: AbbVie, AstraZeneca, BeiGene, Janssen, Octapharma; travel grants: BeiGene, Janssen.